Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 20;16(5):100778.
doi: 10.1016/j.waojou.2023.100778. eCollection 2023 May.

Drug hypersensitivity in drug-resistant tuberculosis

Zeynep Yegin Katran  1 , İsmet Bulut  1 , Aylin Babalık  2 , Metin Keren  1 , Fatma Merve Tepetam  1 , Selver Seda Mersin  3 , Cihan Örçen  4 , Tuğçe Yakut  5 , Dilek Yavuz  1
Affiliations

Drug hypersensitivity in drug-resistant tuberculosis

Zeynep Yegin Katran et al. World Allergy Organ J. .

Abstract

Objective: To evaluate drug resıstant tuberculosis patients who developed drug hypersensitivity to antituberculosis drug.

Methods: This was a retrospective study. The primary aim of the study is to determine the demographic and clinical characteristics of patients who develop drug hypersensitivity in drug resistant tuberculosis patients. The secondary aim of the study is to examine the treatment results. Demographic features, tuberculosis diagnostic indicator, clinical signs of developing hypersensitivity reaction, reaction time, and treatment were evaluated.

Results: A total of 25 patients were included in the study. The prevalence of hypersensitivity in drug resistance patients was 11.9%. Twelve (48%) of the cases were women. Mean age (mean ± SD) was 37.24 ± 14.44 years; early type hypersensitivity reaction in 13 (52%). Three patients were isoniazid resistant; 19 patients were multidrug-resistant (MDR); 2 patients were pre-extensive drug resistant (Pre-XDR), 1 patient was extensive drug resistance (XDR) tuberculosis. The most common skin findings were maculopapular eruption and urticaria. But also we had seen ısole angıodema, urtıcarıa and angıoedema, erythema multıforme, lıchenoıd drug eruptıon and drug rash with eosinophilia and systemic symptoms. In patients who developed a hypersensitivity reaction, the responsible agent was identified in 14 cases in total. Among the drugs, pyrazinamide, ethambutol, moxifloxacin, amikacin, para amino salicylic, prothionamide, and cycloserine are the responsible agents. When evaluated in terms of treatment results, 15 (60%) patients successfully completed the treatment.

Conclusion: Our study is the first study in the literature that evaluated the drug hypersensitivity in drug resıstance tuberculosis patients. Drug hypersensitivity that develops with tuberculosis treatment may lead to discontinuation or change in treatment. İt can cause treatment failure, drug resistance, relapse, and even death. In resistant tuberculosis, the already existing resistance pattern may become more difficult to treat. Success can be achieved with the right management in these patients who have few treatment options, more drug side effects, and high treatment failure rates. The established regimen should be curative and prevent recurrence.

Keywords: Drug resıstance tuberculosis; Maculopapular drug eruptıon; Pyrazınamıde; Urticaria.

PubMed Disclaimer

References

    1. World Health Organization . World Health Organization; Geneva: 2021. Global Tuberculosis Report 2021. Licence, CC BY-NC-SA 3.0 IGO.
    1. World Health Organization . World Health Organization; 2015. Guidelines on the Management of Latent Tuberculosis Infection. - PubMed
    1. Khan F.U., Khan A., Khan F.U., et al. Assessment of adverse drug events, their risk factors, and management among patients treated for multidrug-resistant TB: a prospective cohort study from Pakistan. Front Pharmacol. 2022 May 17;13 doi: 10.3389/fphar.2022.876955. PMID: 35656303; PMCID: PMC9152455. - DOI - PMC - PubMed
    1. Massud A., Syed Sulaiman S.A., Ahmad N., Shafqat M., Chiau Ming L., Khan A.H. Frequency and management of adverse drug reactions among drug-resistant tuberculosis patients: analysis from a prospective study. Front Pharmacol. 2022 Jun 2;13 doi: 10.3389/fphar.2022.883483. PMID: 35747749; PMCID: PMC9211428. - DOI - PMC - PubMed
    1. Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017. Ahmad N., Ahuja S.D., Akkerman O.W., et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018 Sep 8;392(10150):821–834. doi: 10.1016/S0140-6736(18)31644-1. PMID: 30215381; PMCID: PMC6463280. - DOI - PMC - PubMed

LinkOut - more resources